Mayo Foundation for Medical Education and Research

Virginia Tech Intellectual Properties, Inc.

Abdul H Fauq

Elliott Richelson

Daniel J McCormick

Yuan-Ping Pang

Bernadette Marie Cusack

Beth Marie Tyler

Mona Boules

Christopher B Eckman

Debra Yager

Sharie Haugabook

Joseph F Poduslo

Paul Carlier

Geoffrey L Curran

Thomas M Wengenack

Albert O Edwards

Christopher J Monceaux

Sharie J Haugabook

Debra M Yager

This document relates to compounds as well as methods and materials involved in modulating neurotransmitter reuptake. For example, compounds, methods for synthesizing compounds, and methods for inhibiting neurotransmitter reuptake are provided. Specifically gamma-amino alcohol derivatives that inhibit the reuptake of neurotransmitters such as dopamine, serotonin, epinephrine or norepinephrine are provided as therapeutic agents for the treatment of depression or anxiety in a mammalian subject.

Inhibiting neurotransmitter reuptake

This invention relates to processes for preparing long-chain fatty acids of Formula I: and salts thereof, as well as intermediates for the processes, wherein Land Lare described herein.

Process for the synthesis of long-chain fatty acids

This document relates to compounds as well as methods and materials involved in modulating neurotransmitter reuptake. For example, compounds, methods for synthesizing compounds, and methods for inhibiting neurotransmitter reuptake are provided.

The invention provides a novel amino acid, neo-tryptophan, as well as polypeptides containing this novel amino acid such as neurotensin analogs. In addition, the invention provides neo-tryptophan derivatives, serotonin-like neo-tryptophan derivatives, and polypeptides containing such derivatives. The invention also provides methods for making neo-tryptophan, neo-tryptophan derivatives, serotonin-like neo-tryptophan derivatives, and compositions containing these compounds. Further, the invention provides methods for inducing a neurotensin response in a mammal as well as methods for treating a mammal having a serotonin recognition molecule.

Neo-tryptophan

The invention features methods of reducing the level of a &#x3b2;-amyloid (A&#x3b2;) polypeptide using anextract. The invention also features methods of producing an active fraction from an extract of. The invention further features a composition containing an active fraction of aextract and an article of manufacture containing such a composition.

Methods of reducing &#x3b2;-amyloid polypeptides

An amino acid composition with improved blood brain barrier permeability comprising an amino acid polymer, wherein the amino acid comprises at least one asparagyl-4-aminobutane or glutamyl-4-aminobutane residue.

Amino acid composition with increased blood brain barrier permeability

The invention features methods of reducing the level of a &bgr;-amyloid (A&bgr;) polypeptide using an Cimicifuga extract. The invention also features methods of producing an active fraction from an extract of Cimicifuga. The invention further features a composition containing an active fraction of a Cimicifuga extract and an article of manufacture containing such a composition.

Growing community of inventors

Jacksonville, FL, United States of America

Abdul H Fauq